Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$49.25 -6.0%	$26.23	$7.57 ▼ $53.85	$2.09B	0.68	595,449 shs	1.01 million shs
GH Guardant Health	$61.88 +0.8%	$50.26	$20.14 ▼ $62.81	$7.72B	1.43	2.39 million shs	1.52 million shs
OPCH Option Care Health	$28.06 -2.4%	$29.92	$21.39 ▼ $35.53	$4.55B	0.79	1.86 million shs	1.90 million shs
RDNT RadNet	$69.59 -0.7%	$58.44	$45.00 ▼ $93.65	$5.35B	1.43	830,058 shs	1.02 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	+1.22%	+280.68%	+402.11%	+202.13%
GH Guardant Health	0.00%	+4.28%	+38.23%	+61.58%	+111.58%
OPCH Option Care Health	0.00%	+1.48%	-3.20%	-8.50%	-9.71%
RDNT RadNet	0.00%	+3.93%	+22.10%	+23.83%	+7.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELC Celcuity	1.0102 of 5 stars	1.5	2.0	0.0	2.4	3.3	0.0
GH Guardant Health	3.3401 of 5 stars	1.5	2.0	4.4	3.5	2.5	0.6
OPCH Option Care Health	4.8163 of 5 stars	3.4	3.0	4.3	3.7	3.3	1.9
RDNT RadNet	3.2716 of 5 stars	1.6	2.0	4.6	3.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	3.00	Buy	$50.60	-1.18% Downside
GH Guardant Health	3.06	Buy	$57.50	-6.84% Downside
OPCH Option Care Health	2.89	Moderate Buy	$35.75	27.98% Upside
RDNT RadNet	3.25	Buy	$71.60	2.34% Upside

Current Analyst Ratings Breakdown

Latest CELC, GH, RDNT, and OPCH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $66.00
8/18/2025	RDNT RadNet	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $70.00
8/13/2025	RDNT RadNet	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$66.00 ➝ $75.00
8/11/2025	RDNT RadNet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight
7/31/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$36.00 ➝ $38.00
7/31/2025	OPCH Option Care Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/31/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$57.00 ➝ $60.00
7/31/2025	GH Guardant Health	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$59.00 ➝ $61.00
7/28/2025	CELC Celcuity	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $60.00
7/28/2025	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $50.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	$3.11 per share	N/A
GH Guardant Health	$739.02M	10.42	N/A	N/A	($1.13) per share	-54.62
OPCH Option Care Health	$5.00B	0.91	$1.60 per share	17.47	$8.25 per share	3.39
RDNT RadNet	$1.83B	2.94	$3.48 per share	20.13	$15.31 per share	4.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$111.78M	-$3.45	N/A	N/A	N/A	N/A	-150.07%	-64.67%	11/13/2025 (Estimated)
GH Guardant Health	-$436.37M	-$3.35	N/A	N/A	N/A	-49.93%	N/A	-28.95%	11/5/2025 (Estimated)
OPCH Option Care Health	$211.82M	$1.25	22.37	22.17	1.75	3.93%	17.53%	7.17%	10/29/2025 (Estimated)
RDNT RadNet	$2.79M	-$0.20	N/A	132.01	N/A	-0.78%	2.41%	0.82%	11/10/2025 (Estimated)

Latest CELC, GH, RDNT, and OPCH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CELC Celcuity	-$0.90	-$1.04	-$0.14	-$1.04	N/A	N/A
8/10/2025	Q2 2025	RDNT RadNet	$0.17	$0.31	+$0.14	$0.43	$488.06 million	$498.23 million
7/30/2025	Q2 2025	GH Guardant Health	-$0.52	-$0.44	+$0.08	-$0.80	$211.19 million	$232.09 million
7/30/2025	Q2 2025	OPCH Option Care Health	$0.40	$0.41	+$0.01	$0.31	$1.35 billion	$1.42 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
OPCH Option Care Health	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	2.24	4.58	4.58
GH Guardant Health	N/A	3.71	3.35
OPCH Option Care Health	0.81	1.52	1.00
RDNT RadNet	0.91	2.00	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
GH Guardant Health	92.60%
OPCH Option Care Health	98.05%
RDNT RadNet	77.90%

Insider Ownership

Company	Insider Ownership
CELC Celcuity	15.77%
GH Guardant Health	6.10%
OPCH Option Care Health	0.64%
RDNT RadNet	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	40	42.43 million	35.73 million	Optionable
GH Guardant Health	2,021	124.71 million	117.10 million	Not Optionable
OPCH Option Care Health	8,088	162.29 million	161.26 million	Optionable
RDNT RadNet	11,021	76.92 million	72.61 million	Optionable

CELC, GH, RDNT, and OPCH Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Grows Position in RadNet, Inc. $RDNT

August 25 at 5:26 AM | marketbeat.com

Advantage Alpha Capital Partners LP Has $3.71 Million Stock Holdings in RadNet, Inc. $RDNT

August 24 at 7:37 AM | marketbeat.com

RadNet (NASDAQ:RDNT) Insider Ranjan Jayanathan Sells 65,598 Shares

August 24 at 4:13 AM | americanbankingnews.com

Russell Investments Group Ltd. Purchases 13,147 Shares of RadNet, Inc. $RDNT

August 24 at 3:51 AM | marketbeat.com

RadNet (NASDAQ:RDNT) Upgraded at Zacks Research

August 22 at 9:58 AM | marketbeat.com

Cornelis Wesdorp Sells 1,500 Shares of RadNet (NASDAQ:RDNT) Stock

August 22 at 8:42 AM | insidertrades.com

RadNet, Inc. $RDNT Shares Acquired by Northwest & Ethical Investments L.P.

August 22 at 4:43 AM | marketbeat.com

Charles Schwab Investment Management Inc. Sells 26,199 Shares of RadNet, Inc. $RDNT

August 22 at 3:26 AM | marketbeat.com

American Century Companies Inc. Acquires 1,063,516 Shares of RadNet, Inc. $RDNT

August 21, 2025 | marketbeat.com

RadNet, Inc. $RDNT Shares Acquired by LPL Financial LLC

August 21, 2025 | marketbeat.com

Analyzing Astrana Health (NASDAQ:ASTH) & RadNet (NASDAQ:RDNT)

August 21, 2025 | americanbankingnews.com

RadNet (NASDAQ:RDNT) Upgraded by Zacks Research to Hold Rating

August 21, 2025 | americanbankingnews.com

Roubaix Capital LLC Takes $4.27 Million Position in RadNet, Inc. (NASDAQ:RDNT)

August 19, 2025 | marketbeat.com

551,537 Shares in RadNet, Inc. $RDNT Bought by Nuveen LLC

August 19, 2025 | marketbeat.com

5 Revealing Analyst Questions From RadNet’s Q2 Earnings Call

August 18, 2025 | finance.yahoo.com

RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)

August 18, 2025 | seekingalpha.com

Invesco Ltd. Sells 210,244 Shares of RadNet, Inc. (NASDAQ:RDNT)

August 18, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Decreases Holdings in RadNet, Inc. (NASDAQ:RDNT)

August 18, 2025 | marketbeat.com

Vanguard Group Inc. Cuts Stake in RadNet, Inc. (NASDAQ:RDNT)

August 18, 2025 | marketbeat.com

Insider Selling: RadNet, Inc. (NASDAQ:RDNT) EVP Sells 17,000 Shares of Stock

August 17, 2025 | marketbeat.com

Neuberger Berman Group LLC Purchases 58,698 Shares of RadNet, Inc. (NASDAQ:RDNT)

August 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CELC, GH, RDNT, and OPCH Company Descriptions

Celcuity NASDAQ:CELC

$49.25 -3.17 (-6.05%)

Closing price 04:00 PM Eastern

Extended Trading

$49.86 +0.60 (+1.23%)

As of 05:17 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Guardant Health NASDAQ:GH

$61.88 +0.48 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$62.24 +0.35 (+0.57%)

As of 05:26 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Option Care Health NASDAQ:OPCH

$28.06 -0.68 (-2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$28.06 +0.00 (+0.00%)

As of 05:14 PM Eastern

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

RadNet NASDAQ:RDNT

$69.59 -0.51 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$68.75 -0.84 (-1.21%)

As of 05:01 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time